Articles Archives

Continuing the Conversation: What Quality Leaders Need to Know About Building Supply Chains for Advanced Therapies

Following Pharmaceutical Commerce’s podcast with Adam Fox, Chief Quality & Regulatory Affairs Officer at Cryoport Systems, we wanted to explore several topics that deserve a deeper look. As cell and gene therapies continue to advance, quality leaders are discovering that supply chains have become an extension of the quality system itself.

Read More

Beyond Clinical Success: Bianca Gustafson on Building Supply Chains That Scale

In a recent Contract Pharma interview, Bianca Gustafson, Senior Director of Program Management at Cryoport Systems, shared an important perspective on the transition from clinical development to commercialization. According to Gustafson, a common mistake organizations make is assuming that commercial readiness is an extension of clinical operations, when actually commercialization requires a full-on shift in how supply chains are designed and scaled.

Read More

Now Available On Demand: Preventing Advanced Therapy Program Delays with Early Supply Chain Strategy

Advanced therapy programs move through development under intense pressure. Teams are working to reach the clinic, generate data, satisfy regulatory expectations, scale operations, and ultimately deliver therapies to patients who may have limited or no other options. In that environment of competing priorities, all of which are important at the same time, supply chain decisions can become easy to defer. But as a recent roundtable webinar with XTalks made clear, decisions around cryopreservation, logistics, packaging qualification, site readiness, and documentation are not just operational details that can be solved later.

Read More

New eBook: Flexible Infrastructure for Smarter Scale in Advanced Therapies

Advanced therapy developers are being asked to do more with less. Programs need to move faster, reach more patients, support more geographies, and stay ready for evolving regulatory expectations, all while capital remains tightly managed. Cryoport Systems’ new eBook, Flexible Infrastructure: Minimizing CapEx for Smarter Scale in Advanced Therapies, explores that question across the advanced therapy lifecycle. The eBook looks at how developers can preserve capital, reduce operational risk, and avoid overbuilding fixed infrastructure before their programs are ready to use it. 

Read More

Mark Sawicki Joins Base to Base Biotech to Discuss the Future of Cell and Gene Therapy Logistics

Mark Sawicki, President and CEO of Cryoport Systems, recently joined host Jim Cornall on the Base to Base Biotech podcast for a wide-ranging conversation on the evolving cell and gene therapy landscape and the role of specialized supply chain infrastructure in supporting patient access.

Read More

Dominic Clarke on Reducing Variability Before it Becomes a Problem

As cell therapy programs advance, the pressure on supply chains doesn’t usually come from a single breaking point. It builds gradually, often in ways that aren’t immediately visible during early development. In a recent episode of Beyond Biotech, the podcast from Labiotech, Dominic Clarke, Vice President of IntegriCell® Technical Operations at Cryoport Systems, shares what that progression looks like.

Read More

Cryoport Systems in Labiotech on Where CGT Supply Chains Start to Break

As more cell and gene therapy programs push toward later-stage trials and commercialization, a familiar set of pressures is starting to surface. What once felt manageable at smaller scale begins to take more effort to hold together as volumes pick up. A recent article in Labiotech, developed in collaboration with Cryoport Systems, looks closely at where that strain comes from and how it often traces back to decisions made much earlier in development.

Read More

Cryoport Systems Wins CPHI Pharma Award for Supply Chain Excellence

We are proud to announce that Cryoport Systems has been awarded the prestigious Supply Chain Excellence Award at the 2025 CPHI Pharma Awards, a recognition that celebrates innovation, impact, and leadership in pharmaceutical supply chain management. This honor reflects our unwavering commitment to transforming the way life-saving therapies are managed and delivered to patients across the globe.

Read More

A Glimpse Inside the Future of ATMP Supply Chains: Alison Pritchard on the Beyond Biotech Podcast

In an industry where innovation moves fast but patient access often lags behind, how can we build supply chains that are not only compliant and efficient, but also flexible and ready to scale?  That’s the question Alison Pritchard, Vice President of Business Development for Cryoport Systems, tackles in her recent interview with Beyond Biotech, the podcast from Labiotech.eu. Alison explores the state of the advanced therapy medicinal products (ATMP) market in 2025 and what it will take to meet the rising expectations of therapeutic developers, regulators, and – most importantly – patients. 

Read More